AOP Orphan Chief Executive Officer & Executive Board of Directors Change

Since its foundation in 1996 AOP Orphan Pharmaceuticals AG has successfully grown from a single person organization to a fully integrated worldwide acting orphan pharmaceutical company with more than 200 employees. To prepare for the next stage of growth and expansion it has now been decided to enhance the management capacity through the implementation of a new leadership structure: Executive Board of Directors supported by the Executive Management Team.

After more than twenty years as CEO of AOP Orphan Pharmaceutical AG, Dr Rudolf Widmann has handed over the CEO function to Mr Andreas Steiner, who has been in his former role as CFO already a board member and instrumental for the development for AOP for the last five years. Dr. Widmann remains a member in the Executive Board with full focus on Research & Development. The Executive Board is completed by Dr Guenther Krumpl, a highly experienced medical and pharmaceutical expert, who will focus on Strategic Corporate Development.

The Executive Management Team is formed by high level professionals, most of them graduated in natural science and have acquired extensive research experience from both university institutions and industry research facilities. This Team takes responsibility for implementation and execution of AOP Orphan ambitious expansion plans.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)